The earnings call presented a mix of positive and negative aspects. While there were promising signs of new coach growth and improved productivity, the company faced substantial revenue decline, a decrease in active earning coaches, and reported an operational and net loss. Although there are efforts to adapt to the changing market, significant challenges remain.
Company Guidance
During the Medifast First Quarter 2025 Earnings Conference Call, the company provided detailed guidance and insights into its performance and strategic direction. Medifast reported first-quarter revenue of $115.7 million, marking a decrease of 33.8% compared to the previous year, primarily attributed to a 32.8% reduction in active earning OPTAVIA coaches, which totaled approximately 25,400. The average revenue per active earning coach was $4,556, showing a year-over-year decline of 1.4%. The gross profit for the quarter was $84.2 million, matching the 72.8% margin of the previous year, despite lower sales volumes. SG&A expenses decreased by 28.4% to $85.5 million, with significant reductions in coach compensation, market research, and employee compensation. The company posted a net loss of $0.8 million or $0.07 per share, compared to a net income of $8.3 million or $0.76 per diluted share in the previous year. Medifast's balance sheet remains robust with $164.6 million in cash and no interest-bearing debt as of March 31, 2025. Looking ahead, the company anticipates second-quarter revenue between $85 million and $105 million and a potential per-share loss ranging from zero cents to $0.55. Despite challenges, Medifast is focusing on leveraging its coach community and evolving product mix to drive future growth and improve coach productivity. The company highlighted the ongoing impact of GLP-1 medications on weight loss, emphasizing the role of its OPTAVIA program in supporting long-term health goals, preserving lean muscle mass, and improving overall health and wellness.
New Coach Growth
Q1 2025 marked the first meaningful year-over-year increase in new coaches in the past three years, with a double-digit increase compared to the same period last year.
Improved Coach Productivity
For the fourth consecutive quarter, lower year-over-year coach productivity declines were observed, driven by increased productivity of newer coach cohorts.
Strong Cash Position
Medifast ended Q1 2025 with $164.6 million in cash and cash equivalents and no interest-bearing debt.
High Gross Profit Margin
Gross profit margin for the current quarter was 72.8%, consistent with the year-earlier period.
---
Medifast (MED) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MED Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 28, 2025
$12.58
$12.50
-0.64%
Feb 18, 2025
$16.13
$14.29
-11.41%
Nov 04, 2024
$18.81
$20.40
+8.45%
Aug 05, 2024
$20.86
$20.27
-2.83%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Medifast Inc (MED) report earnings?
Medifast Inc (MED) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Medifast Inc (MED) earnings time?
Medifast Inc (MED) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.